Results 191 to 200 of about 37,689 (286)

Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2. [PDF]

ESMO Open
Joris S, Denys H, Collignon J, Rasschaert M, de Roodenbeke DT, Duhoux FP, Canon JL, Tejpar S, Mebis J, Decoster L, Aftimos P, De Grève J.   +11 more
europepmc   +1 more source

Premenopausal Patients With Clinically Aggressive Metastatic Breast Cancer Successfully Treated With a First-Line Palbociclib-Containing Regimen: Two Cases and Literature Review. [PDF]

Cancer Rep (Hoboken)
Fu PA, Hsu YC, Hsu HP, Lin TC, Chung WP.
europepmc   +1 more source

Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer. [PDF]

Sci Rep
Tiede KOM, Teixeira MF, Moura M, Chiaini O, Moura F, Sonbol MB, Borad M, Bekaii-Saab T, Junior PLSU.   +8 more
europepmc   +1 more source

Catalytic Asymmetric Synthesis of Morpholines. Using Mechanistic Insights To Realize the Enantioselective Synthesis of Piperazines.

Journal of Organic Chemistry, 2016
Ying Yin Lau, H. Zhai, L. Schafer
semanticscholar   +1 more source

Driving tert-butyl axial: the surprising cyclopropyl effect. [PDF]

Chem Sci
Izzotti AR, Gleason JL.
europepmc   +1 more source

First- Versus Second- or Subsequent-Line Use of Cyclin-Dependent Kinase 4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic or Recurrent Breast Cancer: A Multicenter, Retrospective Cohort Study. [PDF]

Medicina (Kaunas)
Yao S, Imoto S, Tsuchiya A, Isaka H, Seki H, Asaga S, Yokoi S, Koneri K, Maeda H, Goi T.   +9 more
europepmc   +1 more source

Olaparib maintenance therapy for recurrent adult granulosa cell tumors: A case report. [PDF]

J Obstet Gynaecol Res
Tsukahara H, Onoyama I, Hachisuga K, Yagi H, Yahata H, Kato K.   +5 more
europepmc   +1 more source

The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study. [PDF]

Sci Rep
Oruç A, Deliktaş Onur İ, Uyar GC, Şahin TK, Tünbekici S, Arslan Kapuci A, Ulukal Karancı E, Kemik F, Yıldırım Dişli Ş, Ateş Ö, İnanç İmamoğlu G, Aksoy S, Çakar B, Özdemir N, Öztürk B, Selçukbiricik F, Koçak MZ, Karakurt Eryılmaz M, Araz M, Artaç M.   +19 more
europepmc   +1 more source

Dolutegravir concentrations in children receiving 3-month weekly isoniazid and rifapentine (3HP) for tuberculosis prevention. [PDF]

Microbiol Spectr
Madzime RJ, van der Laan L, du Toit S, Barnabas S, Courtney I, Brown NE, Savic R, Solans BP, Dixon MG, Tsirizani L, Denti P, Boyd R, Hesseling AC, TBTC Study 35 team.   +13 more
europepmc   +1 more source